Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2021 / Cilt: 74 - Sayı: 2

Investigation of the Effect of the Antiaggregant Agent Ticagrelor on the Electrical and Mechanical Activities of Rat Heart With Type 1 Diabetes

Tip 1 Diyabetli Sıçan Kalbi Elektriksel ve Mekanik Aktivitelerine Antiagregan Ajan Tikagrelorun Etkisinin İncelenmesi

Pages
206–212
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, TICA treatment was further prolonged half relaxation time of left ventricular pressure, which was also prolonged in the DM group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Diabetes mellitus (DM) is presently a worldwide health problem and leads to high risks for cardiovascular disfunction.
📊
Key Findings & Data:In this study, we aimed to examine the effect of P2Y12 receptor blocker ticagrelor (TICA) on heart function of DM rats.
💡
Conclusion & Impact:However, TICA treatment was further prolonged half relaxation time of left ventricular pressure, which was also prolonged in the DM group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Diabetes mellitus (DM) is presently a worldwide health problem and leads to high risks for cardiovascular disfunction. Besides vascular disorders in dependent diabetic-cardiomyopathy, high thrombocyte reactivity is developed in DM. In this study, we aimed to examine the effect of P2Y12 receptor blocker ticagrelor (TICA) on heart function of DM rats. Materials and Methods: DM was induced by a single-dose of streptozotocin (STZ) injection in 3-month-old Wistar male rats (250-300g) and confirmed by blood glucose level, 48-hour following STZ-injection. After DM confirmation, those animals were kept for 8 weeks and then, they were divided into two groups. One half DM rats was treated with TICA (150 mg/kg/day, orally) for 4 weeks (DM+TICA group), while the second half group was treated with water (DM group). A third group of rats was treated with only water (Con-group). In situ electrocardiography (ECG)-recording was performed under mild anesthesia and mechanical activities of isolated hearts were examined by Langendorff-perfusion-system. Results: The body weight of the DM group was significantly reduced compared to the Con group (p0.05). Furthermore, TICA treatment did not affect reduced left ventricular pressure and increased left ventricular enddiastolic pressure of the DM group. However, TICA treatment was further prolonged half relaxation time of left ventricular pressure, which was also prolonged in the DM group (p

Özet

Amaç: Günümüze diabetes mellitus (DM) yaygın olarak görülmekte olup kardiyovasküler bozukluklar için önemli bir risk faktörüdür. DM’li hastalarda vasküler bozukluklardan bağımsız olarak gelişen diyabetik kardiyomiyopati yanında, yüksek trombosit-reaktivitesi gelişmektedir. Bu çalışmada, bir P2Y12 reseptör blokörü tikagrelorun (TİKA), DM’li sıçan kalp fonksiyonuna etkisinin incelenmesi hedeflenmiştir. Gereç ve Yöntem: Bu çalışmada ağırlıkları 250-300 gr arasında değişen Wistar türü erkek sıçanlar kullanılarak bir grup sıçana tek doz streptozotosin (STZ; 50 mg/kg) uygulanarak DM (48-saat sonra kan şekeri ölçülerek) oluşturulmuştur. DM olan sıçanların bir grubuna 8 hafta sonra gavaj yoluyla TİKA (150 mg/kg/gün) 4 hafta boyunca uygulanmıştır (DM+TİKA grubu). STZ enjekte edilen ikinci gruba bu süre içinde su uygulanmıştır (DM grubu). Üçüncü grup sıçana aynı süre su uygulanmıştır (Kon grubu). Uygulama sonrasında sıçanlarda hafif anestezi altında in situ elektrokardiyografi (EKG) kaydedilmiş ve kalpler izole edilerek Langendorff-perfüzyon sisteminde kalbin mekanik aktivitesi ölçülmüştür. Bulgular: Hem DM’li hem de DM+TİKA’lı grup sıçanların kilo kaybederek, vücut-ağırlıklarının Kon-grubuna göre önemli derecede azalmış olduğu (p0,05) gözlenmiştir. Ayrıca, DM’li grupta deprese olan sol ventrikül-içi basınç ile ve sol ventrikül-içi diyastol sonu basınç değişimlerinin DM+TİKA’lı grupta da benzer olduğu, buna karşın DM’li grupta uzamış olan gevşeme süresinin bu grupta daha fazla uzamış olduğu gözlenmiştir (p

🔖

Cite This Article

DURAK, A., TUNCAY, E., DEĞİRMENCİ, S., TURAN, B. (2022). Investigation of the Effect of the Antiaggregant Agent Ticagrelor on the Electrical and Mechanical Activities of Rat Heart With Type 1 Diabetes. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 74 - Sayı: 2, 206–212. https://ajindex.com/articles/443499

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Andersson C, Lyngbæk S, Nguyen CD, et al. Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA. 2012;308:882-889
  2. Hu L, Chang L, Zhang Y, et al. Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus. Circulation. 2017;136:817-833
  3. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123:798-813
  4. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26:417-422
  5. Wisman PP, Roest M, Asselbergs FW, et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:736-747
  6. Ozturk C, Unlu M, Yildirim AO, et al. The progressed atrioventricular block associated with ticagrelor therapy may not require permanent pacemaker after acute coronary syndrome; it may be reversible. Int J Cardiol. 2016;203:822-824
  7. He M, Li D, Zhang Y, et al. Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease. Platelets. 2019;30:752-761
  8. Yang XM, Gadde S, Audia JP, et al. Ticagrelor Does Not Protect Isolated Rat Hearts, Thus Clouding Its Proposed Cardioprotective Role Through ENT 1 in Heart Tissue. J Cardiovasc Pharmacol Ther. 2019;24:371-376
  9. Li DT, Li SB, Zheng JY, et al. Analysis of Ticagrelor’s Cardio-protective Effects on Patients with ST-segment Elevation Acute Coronary Syndrome Accompanied with Diabetes. Open Med (Wars). 2019;14:234-240
  10. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent STsegment Elevation. Rev Esp Cardiol (Engl Ed). 2015;68:1125
  11. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease